Is CORT a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Corcept Therapeutics (CORT) rests on Cushing's / hypercortisolism growth runway: Corcept has spent years educating endocrinologists that hypercortisolism is underdiagnosed, and that effort is showing up in record new-patient starts and record new prescribers. The bear case rests on revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. Analysts covering it publish targets from $50.00 to $135.00 against a $93.11 price, so even the professionals disagree by 92% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Corcept Therapeutics is a commercial-stage pharmaceutical company focused on disorders driven by excess cortisol activity. Its foundation is Korlym (mifepristone), a glucocorticoid receptor modulator approved for hypercortisolism (Cushing's syndrome), which generated the bulk of its ~$761 million in 2025 revenue. The company has spent years building physician awareness that hypercortisolism is more common than historically recognized, driving record new-patient starts, and it is expanding beyond a single product: the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026, and Corcept resubmitted a New Drug Application for relacorilant in Cushing's syndrome in June 2026. The investment picture is unusual for biotech: Corcept is consistently profitable, carries zero debt, and held roughly $515 million in cash and investments as of March 2026. Management raised full-year 2026 revenue guidance to a $950 million to $1.05 billion range. The counterweight is concentration and legal risk. A court ruling cleared a path for Teva's generic version of Korlym, threatening the franchise that still funds nearly everything, so the bull case rests on relacorilant approvals and the oncology pipeline replacing and outgrowing branded Korlym before generic erosion bites.
The bull case: what would have to be true for $135.00
The most optimistic published target on CORT is $135.00, +45.0% from the $93.11 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Cushing's / hypercortisolism growth runway
Corcept has spent years educating endocrinologists that hypercortisolism is underdiagnosed, and that effort is showing up in record new-patient starts and record new prescribers. The 2025 franchise grew tablets sold by roughly 37 percent year over year, and management has cited capacity constraints (not demand) as a past limiter, suggesting room to convert latent demand into revenue.
2. Relacorilant as the next-generation successor
Relacorilant is Corcept's proprietary, patent-protected selective cortisol modulator designed to avoid mifepristone's off-target effects. Corcept resubmitted its Cushing's NDA in June 2026 after an earlier complete response letter. If approved, relacorilant could migrate the Cushing's base onto a differentiated, longer-dated-IP molecule and blunt the impact of generic Korlym.
3. Oncology optionality via Lifyorli
The March 2026 FDA approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer opened a second commercial franchise, with U.S. sales beginning in April 2026. Corcept is running additional cortisol-modulation studies across ovarian, endometrial, cervical, pancreatic and other solid tumors, giving the story a pipeline that is independent of the Cushing's cash cow.
4. Self-funded, debt-free balance sheet
Unlike most clinical-stage biotech, Corcept funds its trials and launches from operating cash flow rather than dilution or debt. With no debt and roughly half a billion dollars in cash and investments, it can absorb heavy launch spending (Lifyorli commercialization pushed it to a Q1 2026 loss) without an urgent financing need.
The bear case: what would have to be true for $50.00
The most pessimistic published target is $50.00, -46.3% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Corcept Therapeutics is worth if the risks below bite instead of the drivers above.
Revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. Relacorilant approval is not guaranteed, as evidenced by an earlier FDA complete response letter before the June 2026 resubmission. Teva has also raised antitrust-style allegations about Corcept's distribution and patent practices, adding litigation overhang. The stock trades at a rich trailing earnings multiple, so any disappointment in guidance, approvals, or generic timing can drive sharp drawdowns, and the oncology launch is early and unproven at scale.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CORT already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on CORT
4 analysts cover CORT, with an average target of $92.00 (-1.2% against $93.11) and a split of 3 buy, 0 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CORT forecast and price target page.
How is CORT valued? (as of July 2026)
Snapshot for CORT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$770M
- FY2025 revenue: ~$761M
- FY2026 revenue guidance: ~$950M to $1.05B
- Market cap: ~$9.4B
- P/E (TTM): ~50x
- Cash & investments / debt: ~$515M / no debt
Corcept is profitable on a full-year basis but posted a Q1 2026 net loss of roughly $32 million as it ramped Lifyorli launch spending (SG&A near $145 million, R&D near $66 million). The trailing P/E near 50x reflects a growth-and-optionality premium rather than a value multiple. The zero-debt balance sheet and half-billion-dollar cash cushion give it flexibility to fund launches and litigation internally.
How do you decide if CORT is a buy?
Rather than asking whether CORT is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CORT indirectly through an index or sector ETF before adding more.
What would change your mind on CORT
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Cushing's / hypercortisolism growth runway stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the CORT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CORT against your real portfolio and see your actual exposure before deciding.
Investing in Corcept Therapeutics with AI
Connect the broker you already use and ask Walnut's AI how CORT fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is CORT a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Cushing's / hypercortisolism growth runway, with revenue (ttm) at ~$770M. The bear case rests on revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. Analysts covering it are spread from $50.00 to $135.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell CORT?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $50.00, -46.3% from the $93.11 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for CORT?
+
Cushing's / hypercortisolism growth runway. Corcept has spent years educating endocrinologists that hypercortisolism is underdiagnosed, and that effort is showing up in record new-patient starts and record new prescribers. The most optimistic analyst target on CORT is $135.00, +45.0% from the $93.11 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for CORT?
+
Revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. Relacorilant approval is not guaranteed, as evidenced by an earlier FDA complete response letter before the June 2026 resubmission. Teva has also raised antitrust-style allegations about Corcept's distribution and patent practices, adding litigation overhang. The stock trades at a rich trailing earnings multiple, so any disappointment in guidance, approvals, or generic timing can drive sharp drawdowns, and the oncology launch is early and unproven at scale. The most pessimistic published target is $50.00, -46.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Corcept Therapeutics do?
+
Corcept Therapeutics is a commercial-stage pharmaceutical company focused on disorders driven by excess cortisol activity.
What would have to change for CORT to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Cushing's / hypercortisolism growth runway) stalling in the reported numbers rather than in the narrative, the risk above (revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Corcept Therapeutics actually sell?
+
Its main product is Korlym (mifepristone), a cortisol-blocking drug approved for hypercortisolism in Cushing's syndrome, which drives most of its revenue. In March 2026 the FDA also approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer, adding a second commercial product.
Is Corcept profitable?
+
Yes, on a full-year basis. It generated roughly $761 million in 2025 revenue and has been consistently profitable, though it reported a Q1 2026 net loss of about $32 million because of heavy spending to launch Lifyorli. It carries no debt and holds around $515 million in cash and investments.
What is the biggest risk to CORT?
+
Revenue concentration in Korlym combined with generic competition. A court ruling cleared a path for Teva's generic mifepristone, which could erode the franchise that funds most of the company before newer products fully scale.
Walnut is informational, not investment advice, and gives no verdict on CORT. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.